Literature DB >> 6327834

Secretory IgA antibody in cervicovaginal secretions from women with genital infection due to herpes simplex virus.

H Merriman, S Woods, C Winter, A Fahnlander, L Corey.   

Abstract

Sequential samples of cervicovaginal secretions from women with untreated first and recurrent episodes of genital infection due to herpes simplex virus type 2 (HSV-2) were assayed for IgA antibodies to HSV-2 by using fluorescent antibodies to human secretory piece (sIgA) and human IgA. Among women with first-episode genital herpes, sIgA antibody to HSV-2 was detected in 20 of 31 women from whom HSV was isolated from the cervix, compared with four of 13 women from whom it was not (P less than .05). Among women with first-episode genital herpes, the mean titer of sIgA antibody to HSV-2 peaked between days 9 and 16 of disease, whereas among women with recurrent genital HSV, the peak occurred at days 3-8 of disease. HSV-2 was not isolated from the cervix from any of 130 samples taken when titers of sIgA antibody to HSV-2 were greater than or equal to 1:2, compared with 98 of 259 samples taken when titers were less than or equal to 1:2 (P less than or equal to .01).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327834     DOI: 10.1093/infdis/149.4.505

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  Local immunity and the uterine cervix: implications for cancer-associated viruses.

Authors:  J K Roche; C P Crum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection.

Authors:  R Ashley; A Wald; L Corey
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

5.  Surface expression of secretory component and HLA class II DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines.

Authors:  A C Menge; J Mestecky
Journal:  J Clin Immunol       Date:  1993-07       Impact factor: 8.317

6.  Expression of immunity to intravaginal herpes simplex virus type 2 infection in the genital tract and associated lymph nodes.

Authors:  M R McDermott; P L Brais; G C PLoettsche; M J Evelegh; C H Goldsmith
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

7.  Secretory IgA against herpes simplex virus in cervical secretions.

Authors:  E Persson; P Eneroth; S Jeansson
Journal:  Genitourin Med       Date:  1988-12

8.  Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques.

Authors:  B L Lohman; C J Miller; M B McChesney
Journal:  J Immunol       Date:  1995-12-15       Impact factor: 5.422

9.  Cervical antibodies to herpes simplex virus proteins in pregnancy and puerperium: a pilot study.

Authors:  D H Watts; J M Guise; Z Brown; L Corey; R L Ashley
Journal:  Infect Dis Obstet Gynecol       Date:  1996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.